(NASDAQ: NKTR) Nektar Therapeutics's forecast annual revenue growth rate of -16.52% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 101.28%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.62%.
Nektar Therapeutics's revenue in 2025 is $62,600,000.On average, 10 Wall Street analysts forecast NKTR's revenue for 2025 to be $902,556,304, with the lowest NKTR revenue forecast at $797,390,289, and the highest NKTR revenue forecast at $1,051,660,151. On average, 10 Wall Street analysts forecast NKTR's revenue for 2026 to be $868,321,410, with the lowest NKTR revenue forecast at $478,434,173, and the highest NKTR revenue forecast at $1,162,806,594.
In 2027, NKTR is forecast to generate $719,990,543 in revenue, with the lowest revenue forecast at $161,471,533 and the highest revenue forecast at $1,226,536,792.